Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03178825 · ClinicalTrials.gov registry record · NA
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
A NA study of Sexual Dysfunction and Dyspareunia, sponsored by Sciton.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT03178825: Completed NA study of Sexual Dysfunction and Dyspareunia, sponsored by Sciton.
NCT03178825 is a NA study of Sexual Dysfunction and Dyspareunia that has completed, run by Sciton. The registered enrollment target is 60 participants, below the 965-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03178825, a NA study of Sexual Dysfunction and Dyspareunia, has completed, sponsored by Sciton.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.
Primary Outcome
An objective assessment of vaginal hormone response as well as overall hormonal environment by calculating a ratio of parabasal cells, intermediate cells, and superficial cells
Conditions Studied
Interventions
- DEVICE Hybrid Fractional Laser
Study Locations (6)
California
- Women's Pelvic Health Institute - Los Gatos
Florida
- Coyle Institute - Pensacola
Louisiana
- Louisiana State University - New Orleans
North Carolina
- Carolinas Healthcare System - Charlotte
Texas
- Woodlands Gynecology & Aesthetics - The Woodlands
Virginia
- The Female Pelvic Medicine Institute of Virginia - North Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-05-19 |
| Est. Completion | 2020-02-25 |
| Phase | NA |
What the finished NCT03178825 record still lists
NCT03178825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 965-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (94% lower).
The record links to 5 conditions, with Sexual Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Hybrid Fractional Laser is the first listed.
NCT03178825 lists 6 locations in 6 states (California, Florida, Louisiana).
Frequently Asked Questions
What is clinical trial NCT03178825 about?
NCT03178825 is a clinical study titled "Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause". This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.
What is the current status of trial NCT03178825?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2017-05-19. Estimated completion is 2020-02-25.
What conditions does trial NCT03178825 study?
This clinical trial studies the following conditions: Sexual Dysfunction, Dyspareunia, Vaginal Atrophy, Vaginal Dryness, Chronic UTI.
What interventions are being tested in trial NCT03178825?
The interventions under investigation include: Hybrid Fractional Laser (DEVICE).
Who is sponsoring clinical trial NCT03178825?
This trial is sponsored by Sciton, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03178825 being conducted?
This trial has 6 study locations across California, Florida, Louisiana, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexual Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03178825's enrollment target sits among peer trials
60 11th of 20 higher than 8 of 20 other Sexual Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sexual Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
RECRUITING · NA
-
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
RECRUITING · NA
-
Prostate Stimulation for Sexual Dysfunction
RECRUITING · NA
-
AYA OMGYES Sexual Health Study
RECRUITING · NA
-
Improving Women's Function After Pelvic Radiation
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI